Numerous advancements have been made in treatment options for hematologic malignancies, with a big emphasis on precision medicine. As the field moves forwards with a stronger focus on individualized care, more questions are arising about how we can better identify minimal residual disease, reduce toxicity and identify molecular targets in subsets of patients.
The world’s third most common cancer, colorectal cancer is responsible for an estimated 694,000 annual deaths worldwide. The few last decades have brought great improvements in survival across all stages of the disease. Many factors contributes to this advancement; earlier diagnosis, better pre-operative staging, neoadjuvant radiochemotherapy, refined surgical methods , introduction of pre- and post-operative multidisciplinary team conferences and adjuvant chemotherapy.
Over the past few years, advances in the treatment of skin cancers have improved both overall and progression free survival for patients. However, the sudden and increasing array of immunotherapy and targeted therapy possibilities, and their potential adverse effects, creates complicated questions and considerations for practitioners devising treatment strategies for individuals. In this feature we delve deeper into these advancements to see what oncologists should be focusing on in the year ahead.
The roll out of more effective and affordable screening programes alongside advancements in treatment options have resulted in declining death rates over the last few decades. Despite this, breast cancer remains the most common type of cancer in woman globally with approximately 1.5 million new cases diagnosed each year.